- Home
- RDCM vs TLSA Comparison
RDCM vs TLSA Comparison
Compare RDCM & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDCM
- TLSA
- Stock Information
- Founded
- RDCM 1985
- TLSA 2013
- Country
- RDCM Israel
- TLSA United Kingdom
- Employees
- RDCM N/A
- TLSA 9
- Industry
- RDCM Computer peripheral equipment
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- RDCM Technology
- TLSA Health Care
- Exchange
- RDCM Nasdaq
- TLSA Nasdaq
- Market Cap
- RDCM 215.2M
- TLSA 196.1M
- IPO Year
- RDCM 1997
- TLSA 2000
- Fundamental
- Price
- RDCM $13.09
- TLSA $1.70
- Analyst Decision
- RDCM Strong Buy
- TLSA
- Analyst Count
- RDCM 1
- TLSA 0
- Target Price
- RDCM $18.00
- TLSA N/A
- AVG Volume (30 Days)
- RDCM 43.7K
- TLSA 226.1K
- Earning Date
- RDCM 11-12-2025
- TLSA 01-01-0001
- Dividend Yield
- RDCM N/A
- TLSA N/A
- EPS Growth
- RDCM 37.57
- TLSA N/A
- EPS
- RDCM 0.64
- TLSA N/A
- Revenue
- RDCM $68,901,000.00
- TLSA N/A
- Revenue This Year
- RDCM $18.07
- TLSA N/A
- Revenue Next Year
- RDCM $11.52
- TLSA N/A
- P/E Ratio
- RDCM $19.98
- TLSA N/A
- Revenue Growth
- RDCM 17.27
- TLSA N/A
- 52 Week Low
- RDCM $9.88
- TLSA $0.63
- 52 Week High
- RDCM $15.98
- TLSA $2.60
- Technical
- Relative Strength Index (RSI)
- RDCM 44.27
- TLSA 40.73
- Support Level
- RDCM $12.60
- TLSA $1.60
- Resistance Level
- RDCM $14.44
- TLSA $1.81
- Average True Range (ATR)
- RDCM 0.60
- TLSA 0.13
- MACD
- RDCM -0.05
- TLSA -0.02
- Stochastic Oscillator
- RDCM 24.76
- TLSA 23.40
About RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.